Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(33%)

Phase Distribution

Ph phase_1
1
33%
Ph phase_2
2
67%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(1)
Other(2)

Detailed Status

unknown2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (33.3%)
Phase 22 (66.7%)

Trials by Status

unknown267%
terminated133%

Recent Activity

0 active trials
Showing 3 of 3
unknownphase_2

Intracavernous Injection of Botox 100 U for Treatment of PDE5Is Inconvenient Patients With ED

NCT04172558
unknownphase_1

Intratumoral TriMix Injections in Early Breast Cancer Patients

NCT03788083
terminatedphase_2

iHIVARNA Clinical Trial in HIV Infected Individuals

NCT02888756

Clinical Trials (3)

Showing 3 of 3 trials
NCT04172558Phase 2

Intracavernous Injection of Botox 100 U for Treatment of PDE5Is Inconvenient Patients With ED

Unknown
NCT03788083Phase 1

Intratumoral TriMix Injections in Early Breast Cancer Patients

Unknown
NCT02888756Phase 2

iHIVARNA Clinical Trial in HIV Infected Individuals

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3